BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 2125401)

  • 1. Alterations in vitamin D metabolites during treatment of Paget's disease of bone with calcitonin or etidronate.
    Devlin RD; Gutteridge DH; Prince RL; Retallack RW; Worth GK
    J Bone Miner Res; 1990 Nov; 5(11):1121-6. PubMed ID: 2125401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D in Paget's disease of bone.
    Foldes J; Shamir S; Kidroni G; Menczel J
    Clin Orthop Relat Res; 1989 Jun; (243):275-9. PubMed ID: 2498022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between serum osteocalcin and 24,25-dihydroxyvitamin D levels in Paget's disease of bone.
    Castro-Errecaborde N; de la Piedra C; Rapado A; Alvarez-Arroyo MV; Torres R; Traba ML
    J Clin Endocrinol Metab; 1991 Feb; 72(2):462-6. PubMed ID: 1991815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D status in Paget's bone disease. Effects of calcitonin therapy.
    Nunziata V; Giannattasio R; di Giovanni G; Lettera AM; Nunziata CA
    Clin Orthop Relat Res; 1993 Aug; (293):366-71. PubMed ID: 8339504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum concentrations of vitamin D metabolites in maternal and umbilical cord blood of Libyan and Norwegian women.
    Markestad T; Elzouki A; Legnain M; Ulstein M; Aksnes L
    Hum Nutr Clin Nutr; 1984 Jan; 38(1):55-62. PubMed ID: 6607243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The correlation between the serum levels of osteocalcin and 24,25-dihydroxyvitamin D in Paget's disease of bone].
    Castro Errecarborde N; de la Piedra Gordo C; Rapado Errazti A
    An Med Interna; 1990 Jun; 7(6):286-90. PubMed ID: 2102732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term elevation of 1,25-dihydroxyvitamin D after short-term intravenous administration of pamidronate (aminohydroxypropylidene bisphosphonate, APD) in Paget's disease of bone.
    Devlin RD; Retallack RW; Fenton AJ; Grill V; Gutteridge DH; Kent GN; Prince RL; Worth GK
    J Bone Miner Res; 1994 Jan; 9(1):81-5. PubMed ID: 8154313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D metabolism in osteogenesis imperfecta during calcitonin therapy.
    Nishi Y; Hyodo S; Yoshimitsu K; Sawano K; Yamaoka K; Seino Y; Usui T
    Pediatrics; 1984 Apr; 73(4):538-42. PubMed ID: 6546792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of Paget's disease of bone: diphosphonates or calcitonin?].
    Davoine GA; Jung A; Courvoisier B
    Schweiz Med Wochenschr; 1981 Apr; 111(15):518-24. PubMed ID: 6785879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of 1 alpha-hydroxyvitamin D3 on the mineralization defect in disodium etidronate-treated Paget's disease--a double-blind randomized clinical study.
    Ralston SH; Boyce BF; Cowan RA; Fogelman I; Smith ML; Jenkins A; Boyle IT
    J Bone Miner Res; 1987 Feb; 2(1):5-12. PubMed ID: 3137773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating levels of vitamin D metabolites in patients with hyperinsulinaemia.
    Ishida H; Seino Y; Tsuda K; Matsukura S; Miyamoto Y; Ishizuka S; Imura H
    Hum Nutr Clin Nutr; 1984 Nov; 38(6):473-5. PubMed ID: 6549179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D metabolites in diabetic patients: decreased serum concentration of 24,25-dihydroxyvitamin D.
    Christiansen C; Christensen MS; McNair P; Nielsen B; Madsbad S
    Scand J Clin Lab Invest; 1982 Oct; 42(6):487-91. PubMed ID: 6760373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parathyroid function in Paget's disease of bone.
    Siris ES; Clemens TP; McMahon D; Gordon A; Jacobs TP; Canfield RE
    J Bone Miner Res; 1989 Feb; 4(1):75-9. PubMed ID: 2718781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parathyroid function and vitamin D status in patients with bone metastases of prostatic origin.
    Charhon SA; Chapuy MC; Delvin EE; Meunier PJ
    Miner Electrolyte Metab; 1985; 11(2):117-22. PubMed ID: 3838794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small doses of etidronate (EHDP) and Paget's disease: meaning and importance of the decrease in plasmatic 25(OH)D3.
    D'Amore M; Carrozzo M; Cantatore FP; Scagliusi P; Pipitone V
    Panminerva Med; 1984; 26(1):13-7. PubMed ID: 6233523
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effects of the combined calcitonin and sodium etidronate therapy in Paget's disease of bone].
    Nuti R; Turchetti V; Righi G; Vattimo A
    Minerva Med; 1982 Mar; 73(9):467-72. PubMed ID: 6801555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal vitamin D metabolism in Paget's disease of bone.
    Guillard-Cumming DF; Beard DJ; Douglas DL; Johnson SK; Lawson-Matthew PJ; Russell RG; Kanis JA
    Clin Endocrinol (Oxf); 1985 Apr; 22(4):559-66. PubMed ID: 3872746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of 10 cases of symptomatic Paget's disease with etidronate (EHDP)].
    Jung A; Mermillod B; Schenk R; Courvoisier B; Burkhardt P; Epiney J; Fleisch
    Schweiz Med Wochenschr; 1976 Nov; 106(48):1667-73. PubMed ID: 827810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parathormone, calcitonin, and vitamin D metabolites during normal fracture healing in geriatric patients.
    Meller Y; Kestenbaum RS; Shany S; Galinsky D; Zuili I; Yankovitch N; Giat J; Conforti A; Torok G
    Clin Orthop Relat Res; 1985 Oct; (199):272-9. PubMed ID: 4042489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of Paget's disease with the combined administration of calcitonin and disodium etidronate].
    Ghiringhelli G; Fogel M; Varela de Rodríguez J; Casco C; Mautelén C; Nusimovich B
    Medicina (B Aires); 1982; 42(1):16-20. PubMed ID: 6813634
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.